This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?
by Sundeep Ganoria
IBRX's Anktiva fueled a 700% revenue surge in 2025, but can repeat prescriptions, global expansion and BCG shortages sustain momentum into 2026?
RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change IBRXNegative Net Change
biotechs medical pharmaceuticals
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
by Ekta Bagri
Pfizer and Bristol Myers are racing to strengthen oncology portfolios through deals, new drugs and pipelines ??? investors are weighing which stock stands out.
BMYPositive Net Change PFENegative Net Change
biotechnology biotechs cancer pharmaceuticals
IBRX Stock Jumps on Progress in NK Cell Therapy Production
by Zacks Equity Research
ImmunityBio stock gains more than 7% after completing two programs, showing scalable production of M-ceNK NK cells and early safety data in solid tumor patients.
ANIPNegative Net Change ALXOPositive Net Change IBRXNegative Net Change
biotechs cell-therapy medical
GSK's RSV Vaccine Arexvy Wins FDA Nod for High-Risk Younger Adults
by Zacks Equity Research
GSK secures FDA approval to expand Arexvy's use to high-risk adults aged 18-49 years, broadening access as the company pushes wider global adoption.
GSKPositive Net Change PFENegative Net Change MRNANegative Net Change
biotechs
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
by Zacks Equity Research
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.
JNJPositive Net Change USNAPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia
by Zacks Equity Research
Biotech momentum in 2026 spotlights companies like Liquidia and ANI Pharmaceuticals as pipeline innovation, drug demand and rising M&A activity drive sector interest.
ANIPNegative Net Change ADMANegative Net Change LQDANegative Net Change
biotechnology biotechs medical
4 Biotech Stocks to Watch for Potential Upside in 2026
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
ANIPNegative Net Change ADMANegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
by Sundeep Ganoria
ImmunityBio leverages a persistent BCG shortage and expanding Anktiva use in NMIBC, with 2026 catalysts including FDA talks, global launches and new clinical milestones.
JNJPositive Net Change MRKPositive Net Change IBRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
ImmunityBio Valuation: Paying 33x Sales for Anktiva
by Sundeep Ganoria
IBRX stock surge has pushed valuation to ~33x sales as Anktiva adoption accelerates - but the premium assumes flawless commercialization and expansion.
BMYPositive Net Change MRKPositive Net Change IBRXNegative Net Change
biotechs medical pharmaceuticals
IBRX Stock: Anktiva's Approvals and What Comes Next
by Sundeep Ganoria
ImmunityBio's Anktiva drives revenue surge and new approvals, as U.S. uptake and global launches set up a pivotal 2026.
BMYPositive Net Change MRKPositive Net Change IBRXNegative Net Change
biotechnology biotechs medical pharmaceuticals